M
Miles Dalby
Researcher at Harefield Hospital
Publications - 42
Citations - 1742
Miles Dalby is an academic researcher from Harefield Hospital. The author has contributed to research in topics: Percutaneous coronary intervention & Myocardial infarction. The author has an hindex of 13, co-authored 32 publications receiving 1556 citations. Previous affiliations of Miles Dalby include St Mary's Hospital & National Health Service.
Papers
More filters
Journal ArticleDOI
Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial
Anthony H. Gershlick,Jamal N Khan,Damian J. Kelly,John P Greenwood,Thiagarajah Sasikaran,Nick Curzen,Daniel J. Blackman,Miles Dalby,Kathryn L. Fairbrother,Winston Banya,Duolao Wang,Marcus Flather,Simon Hetherington,Andrew Kelion,Suneel Talwar,Mark Gunning,Roger Hall,Howard Swanton,Gerry P McCann +18 more
TL;DR: In patients presenting for P-PCI with multivessel disease, index admission complete revascularization significantly lowered the rate of the composite primary endpoint at 12 months compared with treating only the IRA.
Journal ArticleDOI
Transfer for Primary Angioplasty Versus Immediate Thrombolysis in Acute Myocardial Infarction A Meta-Analysis
TL;DR: The benefit of primary percutaneous coronary intervention (PCI) over thrombolysis has been clearly demonstrated in acute myocardial infarction (AMI) as discussed by the authors.
Journal ArticleDOI
Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study).
Gilles Montalescot,Claire Bal-dit-Sollier,Daniela Chibedi,Jean-Philippe Collet,Thierry Soulat,Miles Dalby,R.émi Choussat,Ariel Cohen,Michel Slama,Phillipe Gabriel Steg,Jean-Luc Dubois-Randé,Jean-Philippe Metzger,François Tarragano,Jean L Guermonprez,Ludovic Drouet +14 more
TL;DR: Multivariate analysis identified increased plasma levels of von Willebrand factor (vWF) and decreased platelet levels of glycoprotein Ib/IX complexes as independent predictors of 1-month adverse outcome (a composite of death, myocardial infarction, and recurrent ischemia).
Journal ArticleDOI
Eptifibatide provides additional platelet inhibition in Non–ST-Elevation myocardial infarction patients already treated with aspirin and clopidogrel: Results of the platelet activity extinction in Non–Q-Wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study
Miles Dalby,Gilles Montalescot,Claire Bal dit Sollier,Eric Vicaut,Thierry Soulat,Jean-Philippe Collet,Rémi Choussat,Vanessa Gallois,Gérard Drobinski,Ludovic Drouet,Daniel Thomas +10 more
TL;DR: The activated GP IIb/IIIa expression and fibrinogen binding findings indicate that eptifibatide provides significant potent antiplatelet activity above aspirin and clopidogrel, suggesting additive immediate protection in the treatment of NSTEMI.
Journal ArticleDOI
Diurnal variation in platelet aggregation with the PFA–100 platelet function analyser
TL;DR: These findings demonstrate a diurnal rhythm in platelet function using whole blood at high shear rates, likely to be more applicable to the in vivo situation than previously reported optical aggregometry studies.